{"filing":{"accession_number":"0001628280-26-063740","cik":"0001736730","ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"camp-20260928.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026063740/camp-20260928.htm"},"events":[{"id":35493,"run_id":32692,"accession_number":"0001628280-26-063740","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Camp4 Therapeutics disclosed material updates on its clinical development pipeline at an Analyst Day meeting, including detailed information on the ASCEND Phase 1/2 clinical trial for CMP-002 in SYNGAP1-related disorder (with expected first patient dosing by end of 2026 and topline data in H1 2028) and advancement of a preclinical SHANK3 program for Phelan-McDermid Syndrome.","company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39558,"accession_number":"0001628280-26-063740","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports an Analyst Day meeting and updated corporate presentation regarding the Company's planned Phase 1/2 ASCEND clinical trial and pipeline. The filing is made under Item 7.01 (Regulation FD Disclosure), which is a catch-all for non-material investor communications. While the clinical trial itself is operationally significant, the disclosure here is merely furnishing presentation materials from an investor event—a routine communication activity rather than a material event triggering the trial or announcing results. The explicit statement that the information \"shall not be deemed 'filed'\" and the Item 7.01 classification both signal this is administrative disclosure of investor relations materials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:49:50.429610+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39559,"accession_number":"0001628280-26-063740","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Camp4 Therapeutics disclosed material updates on its clinical development pipeline at an Analyst Day meeting, including detailed information on the ASCEND Phase 1/2 clinical trial for CMP-002 in SYNGAP1-related disorder (with expected first patient dosing by end of 2026 and topline data in H1 2028) and advancement of a preclinical SHANK3 program for Phelan-McDermid Syndrome. These are significant operational and strategic milestones for a clinical-stage biopharmaceutical company that would affect a reasonable investor's assessment of the company's pipeline progress and development timeline, but do not fit the specific categories of earnings release, M\u0026A activity, material impairment, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:49:50.429610+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39558,"accession_number":"0001628280-26-063740","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports an Analyst Day meeting and updated corporate presentation regarding the Company's planned Phase 1/2 ASCEND clinical trial and pipeline. The filing is made under Item 7.01 (Regulation FD Disclosure), which is a catch-all for non-material investor communications. While the clinical trial itself is operationally significant, the disclosure here is merely furnishing presentation materials from an investor event—a routine communication activity rather than a material event triggering the trial or announcing results. The explicit statement that the information \"shall not be deemed 'filed'\" and the Item 7.01 classification both signal this is administrative disclosure of investor relations materials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:49:50.429610+00:00","company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","filing_date":"2026-09-28"},{"id":39559,"accession_number":"0001628280-26-063740","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Camp4 Therapeutics disclosed material updates on its clinical development pipeline at an Analyst Day meeting, including detailed information on the ASCEND Phase 1/2 clinical trial for CMP-002 in SYNGAP1-related disorder (with expected first patient dosing by end of 2026 and topline data in H1 2028) and advancement of a preclinical SHANK3 program for Phelan-McDermid Syndrome. These are significant operational and strategic milestones for a clinical-stage biopharmaceutical company that would affect a reasonable investor's assessment of the company's pipeline progress and development timeline, but do not fit the specific categories of earnings release, M\u0026A activity, material impairment, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:49:50.429610+00:00","company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","filing_date":"2026-09-28"}]}